EU regulators are giving drug companies more time to initiate manufacturing-related changes to their approved products in which higher than accepted levels of nitrosamine, or a new nitrosamine, have been detected.
The deadline for sponsors of chemical medicines to submit nitrosamine-related variations has been extended from 26 September 2022 to 1...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?